Plasma Magnesium Concentrations and Risk of Incident Cancer in Adults with Hypertension: A Nested Case-Control Study

2020 ◽  
Vol 76 (5) ◽  
pp. 304-312
Author(s):  
Tengfei Lin ◽  
Chonglei Bi ◽  
Yun Song ◽  
Huiyuan Guo ◽  
Lishun Liu ◽  
...  
Keyword(s):  
Case Control Study ◽  
Smoking Status ◽  
Controlled Trial ◽  
Case Control ◽  
Cancer Site ◽  
Incident Cancer ◽  
Plasma Magnesium ◽  
Nested Case Control ◽  
Risk Of Cancer ◽  
Control Study

<b><i>Objective:</i></b> The association between plasma magnesium and risk of incident cancer remains inconclusive in previous studies. We aimed to investigate the prospective relationship of baseline plasma magnesium concentrations with the risk of incident cancer and to examine possible effect modifiers. <b><i>Methods:</i></b> A nested case-control study with 228 incident cancer cases and 228 matched controls was conducted using data from the China Stroke Primary Prevention Trial (CSPPT), a randomized, double-blind, controlled trial, conducted from May 2008 to August 2013. Study outcomes included incident cancer and its subtypes. <b><i>Results:</i></b> When plasma magnesium concentrations were assessed as quartiles, a significantly higher incident risk of total cancer was found in participants in quartile 1 (&#x3c;0.76 mmol/L; odds ratio [OR] = 2.70; 95% CI: 1.33–5.49) and quartile 4 (≥0.89 mmol/L; OR = 2.05; 95% CI: 1.12–3.76), compared with those in quartile 3 (0.83 to &#x3c;0.89 mmol/L). In cancer site-specific analyses, similar trends were found for gastrointestinal cancer, esophageal cancer, gastric cancer, breast cancer, lung cancer, and other cancers. Furthermore, none of the variables, including age, sex, current smoking status, current alcohol intake, BMI, systolic blood pressure, and total cholesterol levels at baseline significantly modified the association between plasma magnesium and cancer risk. <b><i>Conclusions:</i></b> Both low and high plasma magnesium concentrations were significantly associated with an increased incident risk of cancer, compared with the reference concentrations of 0.83 to &#x3c;0.89 mmol/L among hypertensive adults.

scholarly journals Serum selenium level and cancer risk: a nested case-control study

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Steven A. Narod ◽  
Tomasz Huzarski ◽  
Anna Jakubowska ◽  
Jacek Gronwald ◽  
Cezary Cybulski ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Serum Selenium ◽  
Baseline Serum ◽  
Increased Risk ◽  
Low Selenium ◽  
Nested Case Control ◽  
Risk Of Cancer ◽  
Control Study

Abstract Background Epidemiologic studies have demonstrated a relationship between selenium status and cancer risk among those with low selenium levels. It is of interest to prospectively evaluate the relationship between selenium and cancer among women who reside in a region with ubiquitously low selenium levels. Methods We performed a nested case-control study of baseline serum selenium levels and cancer risk using data and biological samples from 19,573 females that were participants in a biobanking initiative between 2010 and 2014 in Szczecin Poland. Cases included women with any incident cancer (n = 97) and controls (n = 184) were women with no cancer at baseline or follow-up. Serum selenium was quantified using mass spectroscopy. Results The odds ratio associated being below the cutoff of 70.0 μg/L compared to a level above 70.0 μg/L was 2.29 (95% CI 1.26–4.19; P = 0.007). The risks for women in the two middle categories were similar and suggests that the normal range be between 70 μg/L and 90 μg/L. There was evidence for an increased risk of cancer among women in the highest category of selenium levels (i.e., > 90 μg/L), but this association did not achieve statistical significance (OR = 1.63; 95%CI 0.63–4.19; P = 0.31). Conclusions Results from this study suggest that suggest that the optimum serum level of selenium in women living in Poland should be between 70 μg/L and 90 μg/L.

scholarly journals Risk of Cancer in Patients with Insomnia, Parasomnia, and Obstructive Sleep Apnea: A Nationwide Nested Case-Control Study

2015 ◽  
Vol 6 (11) ◽  
pp. 1140-1147 ◽  
Author(s):  
Hui-Feng Fang ◽  
Nae-Fang Miao ◽  
Chi-Dan Chen ◽  
Trevor Sithole ◽  
Min-Huey Chung
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Case Control Study ◽  
Case Control ◽  
Obstructive Sleep ◽  
Nested Case Control ◽  
Risk Of Cancer ◽  
Control Study

Risk factors for the development of chemotherapy-related hospitalization (CRH) in patients treated with palliative intent: Results of a 9-year nested case control study.

2013 ◽  
Vol 31 (31_suppl) ◽  
pp. 3-3
Author(s):  
Ankit J Kansagra ◽  
Gabriel Brooks ◽  
Jenny Hong Gao ◽  
Layli Jamali ◽  
Meenakshi Kundi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cancer Patients ◽  
Case Control Study ◽  
Palliative Chemotherapy ◽  
Case Control ◽  
Cancer Site ◽  
Cancer Center ◽  
Palliative Intent ◽  
Nested Case Control ◽  
Control Study

3 Background: Palliative chemotherapy is aimed at improving quality of life and increasing life expectancy, without curative intent. Toxicity during palliative treatment defeats the goal of care and increases healthcare cost. We describe the predictors of CRHs among cancer patients treated for palliative intent at a community cancer center. Methods: We conducted a nested case-control study of adult cancer patients who received chemotherapy from Jan 03 to Dec 11. Utilizing a pharmacy database we identified patients who had received chemotherapy for palliative intent. For quality measures cancer center prospectively collects data on all the patients who developed CRH, which was used to identify cases. Hospitalizations were classified as CRH, disease-related or unrelated by a multidisciplinary panel. We frequency matched 2 controls to per case on lines of their chemotherapy treatment (3 groups). We obtained odds ratios (OR) and 95% confidence intervals (CI) from a multivariable logistic regression model on this set of 199 cases and 398 controls to identify predictors of CRH. A two-sided p-value of 0.05 was used for all measures of statistical significance. Results: During the selected period 6,850 patients received chemotherapy, 2,559 (37.3%) for palliative intent. 230 (9%) of 2,559 developed CRH. 76.5 % of CRH happened during the first 3 cycles of chemotherapy, and the mean length of stay was 5 days. Significant predictors on multivariable regression were ECOG score (p = .03), Charlson score (p= .0018), cancer site (p <.006,) abnormal creatinine (p <.0001) and low albumin (p < .007). Conclusions: The results of this mature study demonstrate that patients treated with palliative chemotherapy have a substantial risk of severe hospital-requiring toxicity resulting in morbidity and cost. The finding that risk of severe toxicity is increased among patients with poor PS, multiple comorbidities and renal insufficiency suggests that some events may be avoidable. Furthermore, identified risk factors will enable the development and testing of a predictive model which could be used to identify patients at high risk of CRH prior treatment initiation.

scholarly journals Hyperemesis gravidarum and risk of cancer in offspring, a Scandinavian registry-based nested case–control study

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Kathrine F. Vandraas ◽  
Åse V. Vikanes ◽  
Nathalie C. Støer ◽  
Rebecca Troisi ◽  
Olof Stephansson ◽  
...  
Keyword(s):  
Case Control Study ◽  
Hyperemesis Gravidarum ◽  
Case Control ◽  
Nested Case Control ◽  
Risk Of Cancer ◽  
Control Study ◽  
Cancer In Offspring

A14345 A Nested Case-Control Study on Plasma Vitamin E and Risk of Cancer

2018 ◽  
Vol 36 ◽  
pp. e227
Author(s):  
Jiancheng Wang ◽  
Huiyuan Guo ◽  
Hao Zhang ◽  
Binyan Wang ◽  
Yan Zhang ◽  
...  
Keyword(s):  
Vitamin E ◽  
Case Control Study ◽  
Case Control ◽  
Plasma Vitamin ◽  
Plasma Vitamin E ◽  
Nested Case Control ◽  
Risk Of Cancer ◽  
Control Study

Angiotensin Receptor Blockade and Risk of Cancer in Type 2 Diabetes Mellitus: A Nationwide Case-Control Study

2011 ◽  
Vol 29 (22) ◽  
pp. 3001-3007 ◽  
Author(s):  
Chia-Hsuin Chang ◽  
Jou-Wei Lin ◽  
Li-Chiu Wu ◽  
Mei-Shu Lai
Keyword(s):  
Cancer Incidence ◽  
Case Control Study ◽  
Angiotensin Receptor Blockers ◽  
Case Control ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Angiotensin Receptor ◽  
Incident Cancer ◽  
Risk Of Cancer ◽  
Control Study

Purpose The objective of this case-control study was to evaluate the risk of malignancy in diabetic patients who received angiotensin receptor blockers (ARBs). Patients and Methods A total of 21,750 new diabetic patients who started antihypertensive treatment were identified from the Taiwan National Health Insurance claims database during the period from July 1, 2000, to December 31, 2000. As of December 31, 2007, patients with incident cancer were included as cases and up to four age- and sex-matched controls were selected by risk-set sampling. Logistic regression models were applied to estimate the odds ratios (ORs) and 95% CIs between ARB use and cancer incidence, adjusted for other types of antihypertensive drugs, insulin, oral hypoglycemic agents, statins, and underlying diseases. Results Among the 1,281 patients with incident cancer and 5,104 controls, 333 (26.0%) and 1,341 (26.3%), respectively, received ARBs (OR, 0.98; 95% CI, 0.85 to 1.14). There was no statistically significant association between the effect of ARBs as a class and cancer incidence after adjustment for covariates (OR, 0.94; 95% CI, 0.80 to 1.10). Among the individual ARBs, losartan decreased the risk (OR, 0.78; 95% CI, 0.63 to 0.97) and candesartan (OR, 1.79; 95% CI, 1.05 to 3.06) and telmisartan (OR, 1.54; 95% CI, 0.97 to 2.43) possibly increased the risk of occurrence of malignancy. Conclusion The results did not show an effect of ARBs as a class on increasing cancer incidence in patients with diabetes. However, there was a negative association of losartan but a positive one of candesartan and telmisartan with the overall occurrence of cancer. The underlying mechanism certainly requires further investigation.

Sign in / Sign up

Export Citation Format

Share Document